Not indicated for treatment of gm -ve infections. Not to be used for treatment of patients w/ catheter-related bloodstream or catheter-site infections. Monitor CBC wkly in patients receiving treatment, particularly those receiving for >2 wk, w/ increased hemorrhagic risk, w/ pre-existing myelosuppression, receiving concomitant drugs that produce bone marrow suppression or drugs w/ tendency to decrease Hb, platelet count or function, or w/ chronic infection who have received previous or concomitant antibiotic therapy. Discontinue therapy in patients who develop or have worsening myelosuppression; w/ suspected or confirmed
C. difficile-associated diarrhea is suspected or confirmed. Potential hypoglycemic reactions in diabetic patients. Reports of lactic acidosis; convulsions; thrombocytopenia. May promote overgrowth of non-susceptible organisms. Has not been studied in patients w/ uncontrolled HTN, pheochromocytoma, carcinoid syndrome, untreated hyperthyroidism. Safety & efficacy of treatment >28 days have not been evaluated. Prompt ophth evaluation is recommended if patients experience symptoms of visual impairment eg, changes in visual acuity & colour vision, blurred vision, or visual field defect. Caution in patients w/ severe renal insufficiency; <40 kg. Should be used during pregnancy only if potential benefit justifies potential risk to the fetus. Discontinue treatment prior to or during breast-feeding.